KoBioLabs

KoBioLabs R&D Expenses

The Research & Development Expenses of KoBioLabs (348150.KQ) as of Nov 16, 2026 is 7.57 B KRW. In the previous year, Research & Development Expenses was 6.91 B KRW — a change of 9.66% (higher).

R&D Expenses

7.57 BKRW

YoY

9.66%

Last updated:

Research & Development Expenses of KoBioLabs is 2025 7.57 B KRW. Research & Development Expenses of KoBioLabs was 2024 6.91 B KRW. It decreases by 9.66% higher compared to the previous year.

The KoBioLabs R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2020
8.88 B KRW
Jan 1, 2021
12.50 B KRW
Jan 1, 2022
14.20 B KRW
Jan 1, 2023
14.26 B KRW
Jan 1, 2024
6.91 B KRW
Jan 1, 2025
7.57 B KRW
The KoBioLabs R&D Expenses history
YEARR&D ExpensesYoY
7.57 BKRW+9.66%
6.91 BKRW-51.58%
14.26 BKRW+0.45%
14.20 BKRW+13.62%
12.50 BKRW+40.69%
8.88 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KoBioLabs Stock analysis

What does KoBioLabs do? KoBioLabs Inc., headquartered in Seoul, South Korea, operates in the Health Care sector, specializing in biotechnology. The company focuses on research and development of the microbiome, developing products such as Bioviom and Queens henna FOODOLOGY, as well as new microbiome drugs. It provides commissioned research services and sells its products domestically and internationally. Listed on 18 November 2020, KoBioLabs is active in both domestic and overseas markets. KoBioLabs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KoBioLabs stock

Research & Development Expenses of KoBioLabs is 7.57 B KRW in 2025.

Research & Development Expenses of KoBioLabs changed from 6.91 B KRW to 7.57 B KRW, representing a 9.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses KoBioLabs since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's KoBioLabs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — KoBioLabs

All Key Metrics — KoBioLabs